Objective:To provide reference for the treatment of mixed pathological pain by analyzing the analgesic regimen for one ovarian cancer patient with brain metastases. Methods: The clinical pharmacists could conduct comprehensive and dynamic pain as-sessment,and supply the best evidence by consulting the related literatures and guidelines to assist the clinicians to formulate individu-alized administration regimen. Results: After comprehensive considering the clinical diseases, the characteristics and degree of the pain,the psychological status and the other factors,the analgesic regimen was finally adjusted to be a strong opioid combined with a tri-cyclic antidepressant,an anticonvulsant and a corticosteroid. Consequently, the patient obtained effective analgesic treatment without adverse reactions. Conclusion:The pain caused by ovarian cancer with brain metastasis is often severe and difficult to be treated. In clinics,comprehensive and dynamic pain assessment,standard titration of opioids and rational use of adjuvant drugs based on consider-ing patients' conditions are critical for controlling the pain as soon as possible and improving the quality of life of patients.

Objective To evaluate the efficacy,safety and economy of teriparatide in the treatment of osteoporosis.Methods PubMed,Embase,Cochrane Library,Web of Science,CNKI,WanFang Data,VIP databases and websites related to health technology evaluation were systematically searched to collect high-quality clinical evidence and economic evaluation literature of teriparatide in the treatment of osteoporosis from the inception to January 20,2023.Two researchers independently identified studies,extracted data,assessed the quality of included studies,and descriptive analyzed and summarised the results.Results A total of 25 literatures were included,involving 3 HTA reports,15 systematic review/Meta-analyses and 7 economic studies were included.In terms of effectiveness,the evaluation results showed that teriparatide could improve bone mineral density in patients with osteoporosis,reduce the incidence of vertebral/non-vertebral fractures in primary and secondary osteoporosis and prevent the fractures in postmenopausal osteoporosis compared to bisphosphonates and placebos.In terms of safety,teriparatide was proven to be safe with no elevated risk of adverse drug reactions.In terms of economic cost,teriparatide has a higher cost and economic disadvantage compared with bisphosphonates,however,for people with severe postmenopausal osteoporosis and high risk of fracture,teriparatide can be considered as a potential cost-effect treatment option.Conclusion Teriparatide is effective and safe in the treatment of osteoporosis,but it is not cost-effective advantages compared with the existing other anti-osteoporosis medications.